The HIF-1α/PKM2 Feedback Loop in Relation to EGFR Mutational Status in Lung Adenocarcinoma

References

• Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):1–7. doi:10.1016/j.mcna.2018.12.006.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang Z, Zhang G, et al. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett. 2020;479:31–41. doi:10.1016/j.canlet.2020.03.016.
   PubMed Web of Science ®Google Scholar
• Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9(2):117. doi:10.1038/s41419-017-0063-y.
   PubMed Web of Science ®Google Scholar
• Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1–11. doi:10.1016/j.drup.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Wang JZ, Zhu W, Han J, et al. The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun (Lond). 2021;41(7):560–575. doi:10.1002/cac2.12158.
   PubMed Web of Science ®Google Scholar
• Xu Q, Tu J, Dou C, et al. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma. Mol Cancer. 2017;16(1):178. doi:10.1186/s12943-017-0748-y.
   PubMed Web of Science ®Google Scholar
• Zahra K, Dey T, Ashish Mishra SP, Pandey U, Pyruvate kinase M2 and cancer: The role of PKM2 in promoting tumorigenesis. Front Oncol. 2020; 10:159. doi:10.3389/fonc.2020.00159.
   PubMed Web of Science ®Google Scholar
• Guo C-Y, Yan C, Luo L, et al. Enhanced expression of PKM2 associates with the biological properties of cancer stem cells from A549 human lung cancer cells. Oncol Rep. 2017;37(4):2161–2166. doi:10.3892/or.2017.5438.
   PubMed Web of Science ®Google Scholar
• Hasan D, Gamen E, Abu Tarboush N, Ismail Y, Pak O, Azab B. PKM2 and HIF-1α regulation in prostate cancer cell lines. PLoS One. 2018;13(9):e0203745. doi:10.1371/journal.pone.0203745.
   PubMed Web of Science ®Google Scholar
• Azoitei N, Becher A, Steinestel K, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation. Mol Cancer. 2016;15(1):3. doi:10.1186/s12943-015-0490-2.
   PubMedGoogle Scholar
• Hua Q, Mi B, Xu F, et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Theranostics. 2020;10(11):4762–4778. doi:10.7150/thno.43839.
   PubMed Web of Science ®Google Scholar
• Chai XX, Le YF, Wang JC, et al. Carpesium abrotanoides (L.) Root as a potential source of natural anticancer compounds: targeting glucose metabolism and PKM2/HIF-1α axis of breast cancer cells. J Food Sci. 2019;84(12):3825–3832. doi:10.1111/1750-3841.14953.
   PubMed Web of Science ®Google Scholar
• Makinoshima H, Takita M, Matsumoto S, et al. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J Biol Chem. 2014;289(30):20813–20823. doi:10.1074/jbc.M114.575464.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330(6009):1340–1344. doi:10.1126/science.1193494.
   PubMed Web of Science ®Google Scholar
• Babic I, Anderson ES, Tanaka K, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013;17(6):1000–1008. doi:10.1016/j.cmet.2013.04.013.
   PubMed Web of Science ®Google Scholar
• Nilsson MB, Robichaux J, Herynk MH, et al. Altered regulation of HIF-1alpha in naive- and drug-resistant EGFR-mutant NSCLC: implications for a vascular endothelial growth factor-dependent phenotype. J Thorac Oncol. 2021;16(3):439–451. doi:10.1016/j.jtho.2020.11.022.
   PubMed Web of Science ®Google Scholar
• Yang YC, Cheng TY, Huang SM, et al. Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association. Oncogene. 2016;35(26):3387–3398. doi:10.1038/onc.2015.397.
   PubMed Web of Science ®Google Scholar
• Jin Q, Huang F, Xu X, He H, Zhang Y. High expression of hypoxia inducible factor 1α related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC. Sci Rep. 2021;11(1):1199. doi:10.1038/s41598-020-79801-1.
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhai H, Ouyang Y, et al. Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells. Cancer Cell Int. 2019;19(1):129. doi:10.1186/s12935-019-0845-7.
   PubMedGoogle Scholar
• Liu J, Gao L, Zhan N, et al. Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma. J Exp Clin Cancer Res. 2020;39(1):137. doi:10.1186/s13046-020-01641-8.
   PubMed Web of Science ®Google Scholar
• Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–270.
   PubMed Web of Science ®Google Scholar
• Li TE, Wang S, Shen XT, et al. PKM2 drives hepatocellular carcinoma progression by inducing immunosuppressive microenvironment. Front Immunol. 2020;11:589997. doi:10.3389/fimmu.2020.589997.
   PubMed Web of Science ®Google Scholar
• Huang C, Huang Z, Bai P, Luo G, Zhao X, Wang X. Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis. Onco Targets Ther. 2018;11:2075–2082. doi:10.2147/OTT.S152999.
   PubMed Web of Science ®Google Scholar
• Long L, Chen M, Yuan Y, et al. High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. J Cancer. 2020;11(15):4442–4452. doi:10.7150/jca.42610.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li Y, Ma Y, et al. Yes-associated protein (YAP) binds to HIF-1alpha and sustains HIF-1alpha protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress. J Exp Clin Cancer Res. 2018;37(1):216. doi:10.1186/s13046-018-0892-2.
   PubMedGoogle Scholar
• Esteva-Font C, Jin BJ, Verkman AS. Aquaporin-1 gene deletion reduces breast tumor growth and lung metastasis in tumor-producing MMTV-PyVT mice. FASEB J. 2014;28(3):1446–1453. doi:10.1096/fj.13-245621.
   PubMed Web of Science ®Google Scholar
• Jacoby JJ, Erez B, Korshunova MV, et al. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol. 2010;5(7):940–949. doi:10.1097/JTO.0b013e3181dc211f.
   PubMed Web of Science ®Google Scholar
• Cho A, Hur J, Moon YW, et al. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer. 2016;16(1):224. doi:10.1186/s12885-016-2251-z.
   PubMedGoogle Scholar
• Na II, Byun BH, Kim KM, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010;67(1):76–80. doi:10.1016/j.lungcan.2009.03.010.
   PubMed Web of Science ®Google Scholar
• Park S, Ha S, Lee SH, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS One. 2018;13(1):e0189766. doi:10.1371/journal.pone.0189766.
   PubMed Web of Science ®Google Scholar
• Apostolova I, Ego K, Steffen IG, et al. The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging. 2016;43(13):2360–2373. doi:10.1007/s00259-016-3452-z.
   PubMed Web of Science ®Google Scholar
• Huang CT, Yen RF, Cheng MF, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010;27(1):9–15. doi:10.1007/s12032-008-9160-1.
   PubMed Web of Science ®Google Scholar
• Putora PM, Früh M, Müller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology. 2013;18(4):734–735. doi:10.1111/resp.12083.
   PubMed Web of Science ®Google Scholar
• Caicedo C, Garcia-Velloso MJ, Lozano MD, et al. Role of [18 F] FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41(11):2058–2065. doi:10.1007/s00259-014-2833-4.
   PubMedGoogle Scholar